Reimbursement Resources

Olympus has a full collection of reimbursement materials to help healthcare providers be more informed and to make better economic decisions.

Please contact the Olympus Reimbursement Helpline if you have additional questions and need more information. Coding experts are available to help answer your reimbursement questions.

Olympus Reimbursement Helpline Contact:

Additionally other resources are available to help you keep abreast of the latest economics and financial changes. Please access some of our materials below.

Temporary Implanted Prostatic Devices Added to AUA Clinical Practice Guideline.
The iTind™ procedure is now included in the American Urological Association (AUA) clinical practice guideline for management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), also known as enlarged prostate.
View Press Release

Temporary Implanted Nitinol Device vs. Prostatic Urethral Lift: A Matching-adjusted Indirect Comparison.
This Matching-adjusted Indirect Comparison of published clinical trials showed that the iTind™ procedure had a statistically significant improvement in the safety profile while maintaining equivalent efficacy in change in IPSS, QoL, Qmax, PVR, and SHIM compared to PUL treatment for LUTS secondary to BPH three months following treatment and continuing up to one year after treatment. The poster was presented at the 2023 AUA Annual Meeting and the study was published in the Candian Journal of Urology.
CJU - Article Abstract: Temporarily implanted nitinol device versus prostatic urethral lift for minimally invasive surgical treatment of benign prostatic hyperplasia with lower urinary tract symptoms: a matching-adjusted indirect comparison (

The iTind procedure is intended for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men age 50 and above.